Roxbury Financial LLC Takes $153,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Roxbury Financial LLC bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 288 shares of the medical research company’s stock, valued at approximately $153,000.

Several other hedge funds also recently modified their holdings of the business. Guyasuta Investment Advisors Inc. boosted its stake in Thermo Fisher Scientific by 1.8% in the 4th quarter. Guyasuta Investment Advisors Inc. now owns 105,664 shares of the medical research company’s stock valued at $54,970,000 after buying an additional 1,821 shares in the last quarter. Aveo Capital Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 33.4% in the 4th quarter. Aveo Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $640,000 after purchasing an additional 308 shares during the last quarter. Accretive Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 381.7% in the fourth quarter. Accretive Wealth Partners LLC now owns 2,876 shares of the medical research company’s stock valued at $1,496,000 after purchasing an additional 2,279 shares during the last quarter. WealthPlan Investment Management LLC increased its stake in Thermo Fisher Scientific by 6.1% in the fourth quarter. WealthPlan Investment Management LLC now owns 4,211 shares of the medical research company’s stock valued at $2,190,000 after purchasing an additional 241 shares in the last quarter. Finally, Spinnaker Trust lifted its holdings in Thermo Fisher Scientific by 3.3% during the fourth quarter. Spinnaker Trust now owns 10,609 shares of the medical research company’s stock worth $5,519,000 after acquiring an additional 336 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Raymond James reissued an “outperform” rating and issued a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. TD Cowen upped their price objective on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a report on Friday, January 31st. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Finally, Bank of America decreased their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $658.00.

Thermo Fisher Scientific Stock Down 0.0 %

Shares of Thermo Fisher Scientific stock opened at $532.58 on Friday. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock’s 50-day moving average is $548.45 and its 200 day moving average is $571.01. The firm has a market cap of $203.71 billion, a price-to-earnings ratio of 32.22, a PEG ratio of 3.18 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its board has approved a stock buyback plan on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares in the company, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,125 shares of company stock worth $11,231,699 in the last quarter. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.